234 related articles for article (PubMed ID: 28662704)
1. Thrombocytopenia induced by dabigatran: two case reports.
Kang HG; Lee SJ; Chung JY; Cheong JS
BMC Neurol; 2017 Jun; 17(1):124. PubMed ID: 28662704
[TBL] [Abstract][Full Text] [Related]
2. Dabigatran for the prevention and treatment of thromboembolic disorders.
Enriquez A; Baranchuk A; Redfearn D; Simpson C; Abdollah H; Michael K
Expert Rev Cardiovasc Ther; 2015 May; 13(5):529-40. PubMed ID: 25843430
[TBL] [Abstract][Full Text] [Related]
3. Dabigatran Use after Argatroban for Heparin-induced Thrombocytopenia with Thrombosis: A Case Series and Literature Review.
Wang Y; Zhang K; Yin L; Fu G; Liu Z
Ann Vasc Surg; 2022 Mar; 80():392.e1-392.e7. PubMed ID: 34656708
[TBL] [Abstract][Full Text] [Related]
4. Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve-Induced Thrombin Generation.
Jaffer IH; Stafford AR; Fredenburgh JC; Whitlock RP; Chan NC; Weitz JI
J Am Heart Assoc; 2015 Aug; 4(8):e002322. PubMed ID: 26304938
[TBL] [Abstract][Full Text] [Related]
5. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer.
Schulman S; Goldhaber SZ; Kearon C; Kakkar AK; Schellong S; Eriksson H; Hantel S; Feuring M; Kreuzer J
Thromb Haemost; 2015 Jul; 114(1):150-7. PubMed ID: 25739680
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
7. Warfarin and Newer Agents: What the Oral Surgeon Needs to Know.
Steed MB; Swanson MT
Oral Maxillofac Surg Clin North Am; 2016 Nov; 28(4):515-521. PubMed ID: 27624772
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous Pancreas-Kidney Transplantation in a Patient with Heparin-Induced Thrombocytopenia on Dabigatran Therapy.
Jóźwik A; Lisik W; Czerwiński J; Kosieradzki M
Ann Transplant; 2018 Apr; 23():232-235. PubMed ID: 29622761
[TBL] [Abstract][Full Text] [Related]
9. Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants.
Enriquez A; Lip GY; Baranchuk A
Europace; 2016 Jul; 18(7):955-64. PubMed ID: 25816811
[TBL] [Abstract][Full Text] [Related]
10. [New anticoagulants - direct thrombin inhibitors].
Brand B; Graf L
Ther Umsch; 2012 Nov; 69(11):643-9. PubMed ID: 23117667
[TBL] [Abstract][Full Text] [Related]
11. Effect of direct oral anticoagulants on the risk of delayed bleeding after gastric endoscopic submucosal dissection.
Yoshio T; Tomida H; Iwasaki R; Horiuchi Y; Omae M; Ishiyama A; Hirasawa T; Yamamoto Y; Tsuchida T; Fujisaki J; Yamada T; Mita E; Ninomiya T; Michitaka K; Igarashi M
Dig Endosc; 2017 Sep; 29(6):686-694. PubMed ID: 28295638
[TBL] [Abstract][Full Text] [Related]
12. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Schulman S; Kakkar AK; Goldhaber SZ; Schellong S; Eriksson H; Mismetti P; Christiansen AV; Friedman J; Le Maulf F; Peter N; Kearon C;
Circulation; 2014 Feb; 129(7):764-72. PubMed ID: 24344086
[TBL] [Abstract][Full Text] [Related]
13. Bleeding events with dabigatran or warfarin in patients with venous thromboembolism.
Majeed A; Goldhaber SZ; Kakkar A; Kearon C; Eriksson H; Kreuzer J; Feuring M; Hantel S; Friedman J; Schellong S; Schulman S
Thromb Haemost; 2016 Jan; 115(2):291-8. PubMed ID: 26403199
[TBL] [Abstract][Full Text] [Related]
14. Dabigatran use in a postoperative coronary artery bypass surgery patient with nonvalvular atrial fibrillation and heparin-PF4 antibodies.
Fieland D; Taylor M
Ann Pharmacother; 2012 Jan; 46(1):e3. PubMed ID: 22202498
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
[TBL] [Abstract][Full Text] [Related]
16. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
Baetz BE; Spinler SA
Pharmacotherapy; 2008 Nov; 28(11):1354-73. PubMed ID: 18956996
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
[TBL] [Abstract][Full Text] [Related]
18. A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage: A Single-Center University Hospital Experience.
Kumar R; Smith RE; Henry BL
J Intensive Care Med; 2015 Dec; 30(8):462-72. PubMed ID: 24668159
[TBL] [Abstract][Full Text] [Related]
19. Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
Waks JW; Zimetbaum PJ
Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1461-71. PubMed ID: 24147516
[TBL] [Abstract][Full Text] [Related]
20. Reversing the anticoagulation effects of dabigatran.
Dager WE; Banares L
Hosp Pract (1995); 2017 Apr; 45(2):29-38. PubMed ID: 28335637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
